<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Moderna Inc. fell 1.7% in premarket trading Friday, after the biotechnology company with one of the three COVID-19 vaccines granted emergency use authorization in the U.S. was downgraded by a long-time bullish analyst, saying that “the dream is alive, but valuation moves us to the sidelines. On Thursday, the company had reported a big second-quarter profit beat, but the stock pulled back 0.7% after soaring 20.9% the previous two days to a record close on Wednesday.
...read full article on Market Watch
